- Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma
[作者：Baker, DL; Schmidt, ML; Cohn, SL; Maris, JM; London, WB; Buxton, A; Stram, D; Castleberry, RP; Shimada, H; Sandler, A; Shamberger, RC; Look, AT; Reynolds, CP; Seeger, RC; Matthay, KK,期刊：New England Journal of Medicine, 页码：1313-1323 , 文章类型： Article，,卷期：2010年363-14]
- Background: The survival rate among patients with intermediate-risk neuroblastoma who receive dose-intensive chemotherapy is excellent, but the survival rate among patients who receive reduced doses of chemotherapy for s...
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
[作者：Yu, AL; Gilman, AL; Ozkaynak, MF; London, WB; Kreissman, SG; Chen, HX; Smith, M; Anderson, B; Villablanca, JG; Matthay, KK; Shimada, H; Grupp, SA; Seeger, R; Reynolds, CP; Buxton, A; Reisfeld, RA; Gillies, SD; Cohn, SL; Maris, JM; Sondel, PM,期刊：New England Journal of Medicine, 页码：1324-1334 , 文章类型： Article，,卷期：2010年363-14]
Background: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enha...
- Timing of De Novo Mutagenesis - A Twin Study of Sodium-Channel Mutations
[作者：Vadlamudi, L; Dibbens, LM; Lawrence, KM; Iona, X; McMahon, JM; Murrell, W; Mackay-Sim, A; Scheffer, IE; Berkovic, SF,期刊：New England Journal of Medicine, 页码：1335-1340 , 文章类型： Article，,卷期：2010年363-14]
- De novo mutations are a cause of sporadic disease, but little is known about the developmental timing of such mutations. We studied concordant and discordant monozygous twins with de novo mutations in the sodium channel ...
- Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa (vol 363, pg 629, 2010)
[作者：Keene, DR; Woodley, DT; Chen, M; Riddle, MJ,期刊：New England Journal of Medicine, 页码：1383-1383 , 文章类型： Correction，,卷期：2010年363-14]
-
|